Skip to main content
Premium Trial:

Request an Annual Quote

UK s BII Forms Commercial Arm, Signs First Deal

NEW YORK, May 17 (GenomeWeb News) - The Biosystems Informatics Institute, a UKbioinformatics research initiative, has formed a commercial trading arm that will "facilitate business development and marketing of software tools and fee-for-service offerings in bioinformatics and systems biology," BII said yesterday.

 

The announcement of the trading arm, called Turbinia, coincides with BII's first commercial deal, which sees it securing exclusive rights to distribute software developed at MoscowStateUniversityand "a number of other high-profile Russian institutes."

 

BII said that the technology can be used to dynamically model biochemical pathways and interpret drug effects by including both positive and negative feedback loops, inductive and deductive methods, and prediction of multiple independent outcomes in parallel.

 

BII did not provide a launch date for the commercial version of the software.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.